|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2 detection in mixed gastric carcinoma displays high heterogeneity.
|
25914479 |
2015 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2-positive advanced gastric cancer patients frequently develop resistance to trastuzumab through mechanisms still poorly understood.
|
26919099 |
2016 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2 status was evaluated by IHC (immunohistochemistry) and/or FISH ( fluorescence in situ hybridization) in 41 patients in primary gastric cancer and in paired metastasis.
|
27363700 |
2017 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2, JNK and AKT in human GC specimens are positively associated with each other.
|
27895401 |
2016 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Her2 (ERBB2) is one of the most established therapeutic targets in breast and gastric cancer but agents targeting Her2 have not yet demonstrated anti-tumor activity in MIBC.
|
28205537 |
2017 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2 positive rates may be associated with sex, tumor site, TNM staging system, distant metastasis, lymph node metastasis, Lauren's classification, and differentiation grade in gastric cancer patients.
|
28327158 |
2017 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2-positive human gastric cancer cells (NCI-N87), labelled with 211At-trastuzumab, were dropped on the centre of the CR-39 plate.
|
28658304 |
2017 |
|
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Her2-neu overexpression has a pathogenetic, therapeutic and a controversial prognostic role in gastric cancer. p-53 mutation status and Ki-67 proliferation index are established prognostic markers in many tumors.
|
29697008 |
2018 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2-targeted therapy with trastuzumab and (CF/X) prolonged overall survival (OS) in metastatic HER2neu+ gastric carcinoma (GC).
|
30105460 |
2018 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2-ECD (human epidermal growth factor receptor 2 - extracellular domain) is a prominent therapeutic target validated for treating HER2-positive breast and gastric cancer, but HER2-specific therapeutic options for treating advanced gastric cancer remain limited.
|
30365359 |
2019 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany.
|
30826877 |
2019 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2 status from patients with resectable GC (UICC TNM7 tumor stage Ib-III) will be centrally determined.
|
31126258 |
2019 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER-2 is one of the key targets for the gastric cancer therapy.
|
31277667 |
2019 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer.
|
31423428 |
2019 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2+ GCs were related to male gender (p = 0.007), intestinal type (p = 0.001) and less advanced pTNM stage (p = 0.029).
|
31595457 |
2019 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A humanized monoclonal antibody against ERBB2 is used in neoadjuvant therapy for patients with gastric cancer.
|
24491355 |
2014 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity.
|
24917219 |
2015 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements.
|
15517369 |
2004 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy.
|
31667572 |
2020 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Accordingly, trastuzumab plus chemotherapy has recently become the new standard treatment for HER2-positive advanced GCs.
|
21771023 |
2011 |
|
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Accurate measurement of Human epidermal growth factor receptor (HER2) gene expression is central for breast or stomach cancer therapy orientation and prognosis.
|
28039034 |
2017 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Additionally, preclinical data are showing significant antitumor efficacy of anti-HER2 therapies (particularly monoclonal antibodies directed towards the protein) in in vitro and in vivo models of gastric cancer.
|
18441328 |
2008 |
|
Stomach Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
|
30442682 |
2019 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Affinity Maturation of Monoclonal Antibody 1E11 by Targeted Randomization in CDR3 Regions Optimizes Therapeutic Antibody Targeting of HER2-Positive Gastric Cancer.
|
26225765 |
2015 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
After phase III clinical trials, trastuzumab, anti-Erb-B2 receptor tyrosine kinase 2 (commonly known as ERBB2) and ramucirumab, anti-vascular endothelial growth factor receptor 2 (commonly known as VEGFR2) monoclonal antibodies, were approved and introduced into first- and second-line therapies for patients with advanced/metastatic GC.
|
31662821 |
2019 |